AYTU vs. GLTO, SLGL, INDP, VBIV, COCP, GLYC, NERV, TLPH, KALA, and NRBO
Should you be buying Aytu BioPharma stock or one of its competitors? The main competitors of Aytu BioPharma include Galecto (GLTO), Sol-Gel Technologies (SLGL), Indaptus Therapeutics (INDP), VBI Vaccines (VBIV), Cocrystal Pharma (COCP), GlycoMimetics (GLYC), Minerva Neurosciences (NERV), Talphera (TLPH), KALA BIO (KALA), and NeuroBo Pharmaceuticals (NRBO). These companies are all part of the "pharmaceutical preparations" industry.
Aytu BioPharma (NASDAQ:AYTU) and Galecto (NASDAQ:GLTO) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, earnings, valuation, media sentiment, analyst recommendations, institutional ownership, community ranking, profitability and dividends.
Aytu BioPharma currently has a consensus target price of $5.00, indicating a potential upside of 70.07%. Galecto has a consensus target price of $5.33, indicating a potential upside of 758.69%. Given Galecto's higher possible upside, analysts plainly believe Galecto is more favorable than Aytu BioPharma.
Aytu BioPharma has higher revenue and earnings than Galecto. Aytu BioPharma is trading at a lower price-to-earnings ratio than Galecto, indicating that it is currently the more affordable of the two stocks.
Aytu BioPharma has a beta of -1.23, meaning that its share price is 223% less volatile than the S&P 500. Comparatively, Galecto has a beta of 1.26, meaning that its share price is 26% more volatile than the S&P 500.
Galecto has a net margin of 0.00% compared to Aytu BioPharma's net margin of -14.60%. Aytu BioPharma's return on equity of -31.31% beat Galecto's return on equity.
In the previous week, Aytu BioPharma had 5 more articles in the media than Galecto. MarketBeat recorded 5 mentions for Aytu BioPharma and 0 mentions for Galecto. Aytu BioPharma's average media sentiment score of 0.72 beat Galecto's score of 0.00 indicating that Aytu BioPharma is being referred to more favorably in the media.
Aytu BioPharma received 225 more outperform votes than Galecto when rated by MarketBeat users. Likewise, 67.11% of users gave Aytu BioPharma an outperform vote while only 58.82% of users gave Galecto an outperform vote.
33.5% of Aytu BioPharma shares are owned by institutional investors. Comparatively, 14.2% of Galecto shares are owned by institutional investors. 4.3% of Aytu BioPharma shares are owned by company insiders. Comparatively, 12.1% of Galecto shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Summary
Aytu BioPharma beats Galecto on 10 of the 16 factors compared between the two stocks.
This chart shows the number of new MarketBeat users adding AYTU and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Aytu BioPharma Competitors List
Related Companies and Tools
